<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="9" family="Times,Italic" color="#000000"/>
	<fontspec id="font1" size="9" family="Times,Italic" color="#000000"/>
	<fontspec id="font2" size="12" family="Helvetica,Bold" color="#ffffff"/>
	<fontspec id="font3" size="10" family="Times,Italic" color="#000000"/>
	<fontspec id="font4" size="7" family="Times,Italic" color="#000000"/>
	<fontspec id="font5" size="6" family="Times,Italic" color="#000000"/>
	<fontspec id="font6" size="10" family="Times,Italic" color="#000000"/>
	<fontspec id="font7" size="7" family="Times" color="#000000"/>
	<fontspec id="font8" size="10" family="Times,BoldItalic" color="#000000"/>
	<fontspec id="font9" size="11" family="Helvetica,Bold" color="#000000"/>
<text top="42" left="279" width="54" height="8" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="title">FRASER et al.<i>et al.</i></text>
<text top="754" left="534" width="20" height="11" font="font2" id="p1_t2" reading_order_no="117" segment_no="3" tag_type="text">105<b>105</b></text>
<text top="765" left="227" width="161" height="9" font="font3" id="p1_t3" reading_order_no="116" segment_no="20" tag_type="text">C URRENT O NCOLOGY — V OLUME 14, N UMBER 3<i>C</i></text>
<text top="82" left="73" width="221" height="11" font="font6" id="p1_t4" reading_order_no="1" segment_no="1" tag_type="text">Lundin et al. 15 reported CMV reactivation in 4 pa-<i>URRENT</i></text>
<text top="95" left="55" width="239" height="9" font="font6" id="p1_t5" reading_order_no="2" segment_no="1" tag_type="text">tients (11%) treated with subcutaneous alemtuzumab.<i> O</i></text>
<text top="105" left="55" width="239" height="9" font="font6" id="p1_t6" reading_order_no="3" segment_no="1" tag_type="text">One case of PCP occurred in a patient not receiving<i>NCOLOGY</i></text>
<text top="117" left="55" width="239" height="9" font="font6" id="p1_t7" reading_order_no="4" segment_no="1" tag_type="text">prophylaxis. An update describing the long-term fol-<i>—</i></text>
<text top="128" left="55" width="239" height="9" font="font6" id="p1_t8" reading_order_no="5" segment_no="1" tag_type="text">low-up for that patient cohort documented 1 episode<i>V</i></text>
<text top="138" left="55" width="239" height="9" font="font6" id="p1_t9" reading_order_no="6" segment_no="1" tag_type="text">of symptomatic Epstein–Barr virus (infection<i>OLUME</i></text>
<text top="148" left="55" width="239" height="11" font="font6" id="p1_t10" reading_order_no="7" segment_no="1" tag_type="text">21 months post alemtuzumab therapy) 16 . No other<i> 14, N</i></text>
<text top="161" left="55" width="127" height="9" font="font6" id="p1_t11" reading_order_no="8" segment_no="1" tag_type="text">serious infections occurred.<i>UMBER</i></text>
<text top="177" left="55" width="239" height="9" font="font3" id="p1_t12" reading_order_no="9" segment_no="5" tag_type="text">Alemtuzumab in Combination with Additional Agents<i> 3</i></text>
<text top="187" left="55" width="239" height="10" font="font3" id="p1_t13" reading_order_no="10" segment_no="5" tag_type="text">for Relapsed or Refractory CLL : Faderl et al. 17 docu-<i>et al.</i></text>
<text top="199" left="55" width="239" height="9" font="font6" id="p1_t14" reading_order_no="11" segment_no="5" tag_type="text">mented infections in 52% of patients with lymphoid</text>
<text top="210" left="55" width="239" height="9" font="font6" id="p1_t15" reading_order_no="12" segment_no="5" tag_type="text">malignancies treated with alemtuzumab in combina-</text>
<text top="221" left="55" width="239" height="9" font="font6" id="p1_t16" reading_order_no="13" segment_no="5" tag_type="text">tion with rituximab; CMV reactivation occurred in 27%.</text>
<text top="232" left="55" width="239" height="9" font="font6" id="p1_t17" reading_order_no="14" segment_no="5" tag_type="text">Infections in CLL patients were not reported separately.</text>
<text top="242" left="73" width="221" height="10" font="font6" id="p1_t18" reading_order_no="15" segment_no="6" tag_type="text">Elter 19 reported data on 36 patients treated with</text>
<text top="254" left="55" width="239" height="9" font="font6" id="p1_t19" reading_order_no="16" segment_no="6" tag_type="text">alemtuzumab in combination with fludarabine; fun-</text>
<text top="265" left="55" width="239" height="9" font="font6" id="p1_t20" reading_order_no="17" segment_no="6" tag_type="text">gal pneumonia (n = 2), CMV reactivation (n = 2), and</text>
<text top="276" left="55" width="239" height="9" font="font6" id="p1_t21" reading_order_no="18" segment_no="6" tag_type="text">infection-related death (n = 1 case of Escherichia coli</text>
<text top="287" left="55" width="239" height="9" font="font6" id="p1_t22" reading_order_no="19" segment_no="6" tag_type="text">sepsis) were the only reported infection-related</text>
<text top="298" left="55" width="67" height="9" font="font6" id="p1_t23" reading_order_no="20" segment_no="6" tag_type="text">complications.</text>
<text top="308" left="73" width="221" height="10" font="font6" id="p1_t24" reading_order_no="21" segment_no="7" tag_type="text">Wierda et al. 18 reported CMV reactivation in 24%</text>
<text top="320" left="55" width="239" height="9" font="font6" id="p1_t25" reading_order_no="22" segment_no="7" tag_type="text">of patients (n = 21) treated with alemtuzumab in com-</text>
<text top="331" left="55" width="239" height="9" font="font6" id="p1_t26" reading_order_no="23" segment_no="7" tag_type="text">bination with cyclophosphamide, rituximab, and</text>
<text top="342" left="55" width="55" height="9" font="font6" id="p1_t27" reading_order_no="24" segment_no="7" tag_type="text">fludarabine.</text>
<text top="359" left="55" width="239" height="9" font="font3" id="p1_t28" reading_order_no="25" segment_no="9" tag_type="text">Alemtuzumab Consolidation for Patients with a Re-</text>
<text top="368" left="55" width="239" height="10" font="font3" id="p1_t29" reading_order_no="26" segment_no="9" tag_type="text">sponse to Previous-Line Therapy: Wendtner et al. 20<i>Alemtuzumab in Combination with Additional Agents</i></text>
<text top="381" left="55" width="239" height="9" font="font6" id="p1_t30" reading_order_no="27" segment_no="9" tag_type="text">randomized patients with a response to first-line<i>for Relapsed or Refractory </i></text>
<text top="392" left="55" width="239" height="9" font="font6" id="p1_t31" reading_order_no="28" segment_no="9" tag_type="text">fludarabine-containing chemotherapy to consolida-<i>CLL</i></text>
<text top="402" left="55" width="239" height="9" font="font6" id="p1_t32" reading_order_no="29" segment_no="9" tag_type="text">tion with alemtuzumab (30 mg intravenously 3 times<i>: </i>Faderl <i>et al.</i></text>
<text top="414" left="55" width="239" height="9" font="font6" id="p1_t33" reading_order_no="30" segment_no="9" tag_type="text">weekly for 12 weeks) or observation. Explicit stop-</text>
<text top="425" left="55" width="239" height="9" font="font6" id="p1_t34" reading_order_no="31" segment_no="9" tag_type="text">ping rules were determined a priori and included</text>
<text top="435" left="55" width="239" height="9" font="font6" id="p1_t35" reading_order_no="32" segment_no="9" tag_type="text">grade 3 or 4 infection occurring in 5 of the first 10 pa-</text>
<text top="447" left="55" width="239" height="9" font="font6" id="p1_t36" reading_order_no="33" segment_no="9" tag_type="text">tients accrued to the alemtuzumab arm. The study</text>
<text top="458" left="55" width="239" height="9" font="font6" id="p1_t37" reading_order_no="34" segment_no="9" tag_type="text">was stopped early because of severe infections in 7 of</text>
<text top="468" left="55" width="239" height="9" font="font6" id="p1_t38" reading_order_no="35" segment_no="9" tag_type="text">11 patients randomized to alemtuzumab consolida-</text>
<text top="480" left="55" width="239" height="9" font="font6" id="p1_t39" reading_order_no="36" segment_no="9" tag_type="text">tion. Grades 3 and 4 infections included CMV reacti-</text>
<text top="491" left="55" width="239" height="9" font="font6" id="p1_t40" reading_order_no="37" segment_no="9" tag_type="text">vation (n = 2), CMV pneumonitis (n = 2), pulmonary</text>
<text top="501" left="55" width="239" height="9" font="font6" id="p1_t41" reading_order_no="38" segment_no="9" tag_type="text">aspergillosis and HSV /human herpes virus 6 (n = 1),</text>
<text top="513" left="55" width="239" height="9" font="font6" id="p1_t42" reading_order_no="39" segment_no="9" tag_type="text">pulmonary tuberculosis (n = 1), and herpes zoster</text>
<text top="524" left="55" width="239" height="9" font="font6" id="p1_t43" reading_order_no="40" segment_no="9" tag_type="text">reactivation (n = 1). An additional 2 patients devel-</text>
<text top="534" left="55" width="239" height="9" font="font6" id="p1_t44" reading_order_no="41" segment_no="9" tag_type="text">oped grade 2 CMV reactivation. Overall, 9 of 11 pa-</text>
<text top="546" left="55" width="239" height="9" font="font6" id="p1_t45" reading_order_no="42" segment_no="9" tag_type="text">tients (82%) randomized to alemtuzumab</text>
<text top="557" left="55" width="239" height="9" font="font6" id="p1_t46" reading_order_no="43" segment_no="9" tag_type="text">consolidation discontinued therapy because of an</text>
<text top="567" left="55" width="239" height="9" font="font6" id="p1_t47" reading_order_no="44" segment_no="9" tag_type="text">adverse event (severe infection in 5 patients and se-<i>n</i> = 2), </text>
<text top="579" left="55" width="172" height="9" font="font6" id="p1_t48" reading_order_no="45" segment_no="9" tag_type="text">vere myelosuppression in 4 patients).</text>
<text top="590" left="73" width="221" height="9" font="font6" id="p1_t49" reading_order_no="46" segment_no="15" tag_type="text">Four additional single-arm studies reported in-<i>n</i> = 2), and</text>
<text top="600" left="55" width="239" height="9" font="font6" id="p1_t50" reading_order_no="47" segment_no="15" tag_type="text">fection-related toxicity for alemtuzumab consolida-<i>n</i> = 1 case of <i>Escherichia coli</i></text>
<text top="610" left="55" width="239" height="11" font="font6" id="p1_t51" reading_order_no="48" segment_no="15" tag_type="text">tion therapy 22–25 . Reactivation of CMV was common,</text>
<text top="623" left="55" width="239" height="9" font="font6" id="p1_t52" reading_order_no="49" segment_no="15" tag_type="text">occurring in 21%–57% of patients; the single reported</text>
<text top="632" left="55" width="239" height="10" font="font6" id="p1_t53" reading_order_no="50" segment_no="15" tag_type="text">case of CMV pneumonitis 22 contributed to patient<i>et al.</i></text>
<text top="645" left="55" width="239" height="9" font="font6" id="p1_t54" reading_order_no="51" segment_no="15" tag_type="text">death. The studies evaluated either a 10-mg or 30-mg</text>
<text top="656" left="55" width="239" height="9" font="font6" id="p1_t55" reading_order_no="52" segment_no="15" tag_type="text">dose of alemtuzumab administered over 6 to 8 weeks.</text>
<text top="666" left="55" width="239" height="9" font="font6" id="p1_t56" reading_order_no="53" segment_no="15" tag_type="text">No apparent difference in the rate or severity of in-</text>
<text top="678" left="55" width="206" height="9" font="font6" id="p1_t57" reading_order_no="54" segment_no="15" tag_type="text">fections by treatment regimen was observed.</text>
<text top="699" left="55" width="70" height="9" font="font8" id="p1_t58" reading_order_no="55" segment_no="17" tag_type="title">4.2.3 Question 3<i>n</i> = 21) treated with alemtuzumab in com-</text>
<text top="711" left="55" width="239" height="9" font="font3" id="p1_t59" reading_order_no="56" segment_no="18" tag_type="text">Which patients are more likely—or less likely—to</text>
<text top="722" left="55" width="195" height="9" font="font3" id="p1_t60" reading_order_no="57" segment_no="18" tag_type="text">benefit from treatment with alemtuzumab?</text>
<text top="84" left="336" width="221" height="9" font="font6" id="p1_t61" reading_order_no="58" segment_no="2" tag_type="text">Statistical evaluations for independent predictors<i>Alemtuzumab Consolidation for Patients with a Re-</i></text>
<text top="95" left="318" width="239" height="9" font="font6" id="p1_t62" reading_order_no="59" segment_no="2" tag_type="text">of response, response duration, or survival were not<i>sponse to Previous-Line Therapy: </i>Wendtner <i>et al.</i></text>
<text top="105" left="318" width="239" height="9" font="font6" id="p1_t63" reading_order_no="60" segment_no="2" tag_type="text">reported in any study—including in the present sys-</text>
<text top="117" left="318" width="239" height="9" font="font6" id="p1_t64" reading_order_no="61" segment_no="2" tag_type="text">tematic review. However, several publications re-</text>
<text top="128" left="318" width="239" height="9" font="font6" id="p1_t65" reading_order_no="62" segment_no="2" tag_type="text">ported subgroup analyses and clinical observations</text>
<text top="138" left="318" width="239" height="9" font="font6" id="p1_t66" reading_order_no="63" segment_no="2" tag_type="text">for patients who were more or less likely to respond</text>
<text top="150" left="318" width="77" height="9" font="font6" id="p1_t67" reading_order_no="64" segment_no="2" tag_type="text">to alemtuzumab.</text>
<text top="161" left="336" width="221" height="9" font="font6" id="p1_t68" reading_order_no="65" segment_no="4" tag_type="text">Several authors noted that patients with lymphad-<i>a priori</i> and included</text>
<text top="171" left="318" width="239" height="9" font="font6" id="p1_t69" reading_order_no="66" segment_no="4" tag_type="text">enopathy, particularly bulky lymph nodes (&gt;5 cm),</text>
<text top="183" left="318" width="239" height="9" font="font6" id="p1_t70" reading_order_no="67" segment_no="4" tag_type="text">were less likely to achieve a clinical response to</text>
<text top="192" left="318" width="239" height="11" font="font6" id="p1_t71" reading_order_no="68" segment_no="4" tag_type="text">alemtuzumab-containing therapy 5,7,11,12,15,20,23 .</text>
<text top="203" left="318" width="239" height="10" font="font6" id="p1_t72" reading_order_no="69" segment_no="4" tag_type="text">Keating  et al. 5 reported that patients less likely to</text>
<text top="216" left="318" width="239" height="9" font="font6" id="p1_t73" reading_order_no="70" segment_no="4" tag_type="text">respond included those with Rai stage IV disease, with</text>
<text top="227" left="318" width="239" height="9" font="font6" id="p1_t74" reading_order_no="71" segment_no="4" tag_type="text">at least 1 lymph node greater than 5 cm in diameter,</text>
<text top="237" left="318" width="238" height="9" font="font6" id="p1_t75" reading_order_no="72" segment_no="4" tag_type="text">or with a World Health Organization ( WHO ) perfor-</text>
<text top="247" left="318" width="238" height="11" font="font6" id="p1_t76" reading_order_no="73" segment_no="4" tag_type="text">mance status of 2. Moreton et al. 11 evaluated alem-<i>n</i> = 2), </text>
<text top="260" left="318" width="239" height="9" font="font6" id="p1_t77" reading_order_no="74" segment_no="4" tag_type="text">tuzumab monotherapy administered to maximal</text>
<text top="270" left="318" width="239" height="9" font="font6" id="p1_t78" reading_order_no="75" segment_no="4" tag_type="text">response in patients relapsed or refractory to fludar-<i>n</i> = 2), pulmonary</text>
<text top="282" left="318" width="239" height="9" font="font6" id="p1_t79" reading_order_no="76" segment_no="4" tag_type="text">abine and reported that patients were significantly</text>
<text top="293" left="318" width="239" height="9" font="font6" id="p1_t80" reading_order_no="77" segment_no="4" tag_type="text">less likely to respond if their lymph nodes were larger</text>
<text top="303" left="318" width="239" height="9" font="font6" id="p1_t81" reading_order_no="78" segment_no="4" tag_type="text">than 5 cm (p &lt; 0.0001), if they had received 3 or more<i>n</i> = 1),</text>
<text top="315" left="318" width="239" height="9" font="font6" id="p1_t82" reading_order_no="79" segment_no="4" tag_type="text">previous lines of therapy (p = 0.0005), or if their pre-<i>n</i> = 1), and herpes zoster</text>
<text top="326" left="318" width="239" height="9" font="font6" id="p1_t83" reading_order_no="80" segment_no="4" tag_type="text">treatment WHO performance status was greater than 1.<i>n</i> = 1). An additional 2 patients devel-</text>
<text top="336" left="336" width="221" height="9" font="font6" id="p1_t84" reading_order_no="81" segment_no="8" tag_type="text">The RCT published by the German CLL Study</text>
<text top="346" left="318" width="239" height="11" font="font6" id="p1_t85" reading_order_no="82" segment_no="8" tag_type="text">Group 20 failed to find a correlation between response</text>
<text top="359" left="318" width="239" height="9" font="font6" id="p1_t86" reading_order_no="83" segment_no="8" tag_type="text">status and age, disease stage, response to previous-</text>
<text top="369" left="318" width="239" height="9" font="font6" id="p1_t87" reading_order_no="84" segment_no="8" tag_type="text">line fludarabine-containing chemotherapy, cumula-</text>
<text top="381" left="318" width="239" height="9" font="font6" id="p1_t88" reading_order_no="85" segment_no="8" tag_type="text">tive alemtuzumab dose, duration of alemtuzumab</text>
<text top="392" left="318" width="239" height="9" font="font6" id="p1_t89" reading_order_no="86" segment_no="8" tag_type="text">therapy, IgH mutational status, or cytogenetic aber-</text>
<text top="402" left="318" width="239" height="9" font="font6" id="p1_t90" reading_order_no="87" segment_no="8" tag_type="text">rations. However, their analysis was limited to just</text>
<text top="414" left="318" width="239" height="9" font="font6" id="p1_t91" reading_order_no="88" segment_no="8" tag_type="text">11 patients, because the trial was stopped early be-</text>
<text top="425" left="318" width="239" height="9" font="font6" id="p1_t92" reading_order_no="89" segment_no="8" tag_type="text">cause of excessive severe infections in the alem-</text>
<text top="435" left="318" width="129" height="9" font="font6" id="p1_t93" reading_order_no="90" segment_no="8" tag_type="text">tuzumab-consolidation arm.</text>
<text top="457" left="318" width="85" height="10" font="font9" id="p1_t94" reading_order_no="91" segment_no="10" tag_type="title">5. DISCUSSION</text>
<text top="480" left="318" width="239" height="9" font="font6" id="p1_t95" reading_order_no="92" segment_no="11" tag_type="text">In its deliberations, the Hematology DSG places par-</text>
<text top="491" left="318" width="90" height="9" font="font6" id="p1_t96" reading_order_no="93" segment_no="11" tag_type="text">ticular emphasis on</text>
<text top="513" left="318" width="4" height="9" font="font6" id="p1_t97" reading_order_no="94" segment_no="12" tag_type="list">•</text>
<text top="513" left="336" width="212" height="9" font="font6" id="p1_t98" reading_order_no="95" segment_no="12" tag_type="list">results from published RCT s (where available);</text>
<text top="524" left="318" width="4" height="9" font="font6" id="p1_t99" reading_order_no="96" segment_no="13" tag_type="list">•</text>
<text top="524" left="336" width="221" height="9" font="font6" id="p1_t100" reading_order_no="97" segment_no="13" tag_type="list">recognition of a hierarchy of outcomes that should</text>
<text top="534" left="336" width="221" height="9" font="font6" id="p1_t101" reading_order_no="98" segment_no="13" tag_type="list">influence treatment decisions, with priority given</text>
<text top="546" left="336" width="221" height="9" font="font6" id="p1_t102" reading_order_no="99" segment_no="13" tag_type="list">to therapies found to extend life or improve qual-</text>
<text top="557" left="336" width="65" height="9" font="font6" id="p1_t103" reading_order_no="100" segment_no="13" tag_type="list">ity of life; and</text>
<text top="567" left="318" width="4" height="9" font="font6" id="p1_t104" reading_order_no="101" segment_no="14" tag_type="list">•</text>
<text top="567" left="336" width="221" height="9" font="font6" id="p1_t105" reading_order_no="102" segment_no="14" tag_type="list">the potential toxicities associated with treatment,</text>
<text top="579" left="336" width="221" height="9" font="font6" id="p1_t106" reading_order_no="103" segment_no="14" tag_type="list">with particular emphasis on the toxicities seen in</text>
<text top="590" left="336" width="221" height="9" font="font6" id="p1_t107" reading_order_no="104" segment_no="14" tag_type="list">the patients most likely to make up the popula-</text>
<text top="600" left="336" width="131" height="9" font="font6" id="p1_t108" reading_order_no="105" segment_no="14" tag_type="list">tion eventually to be treated.<i><b>4.2.3 Question 3</b></i></text>
<text top="623" left="336" width="221" height="9" font="font6" id="p1_t109" reading_order_no="106" segment_no="16" tag_type="text">The members of the Hematology DSG had con-<i>Which patients are more likely—or less likely—to</i></text>
<text top="633" left="318" width="239" height="9" font="font6" id="p1_t110" reading_order_no="107" segment_no="16" tag_type="text">siderable difficulty reaching consensus on the appro-<i>benefit from treatment with alemtuzumab?</i></text>
<text top="645" left="318" width="239" height="9" font="font6" id="p1_t111" reading_order_no="108" segment_no="16" tag_type="text">priate wording of the recommendation for a potential</text>
<text top="656" left="318" width="239" height="9" font="font6" id="p1_t112" reading_order_no="109" segment_no="16" tag_type="text">indication for alemtuzumab in patients with CLL . The</text>
<text top="666" left="318" width="239" height="9" font="font6" id="p1_t113" reading_order_no="110" segment_no="16" tag_type="text">recommendation went through multiple iterations (see</text>
<text top="678" left="318" width="239" height="9" font="font6" id="p1_t114" reading_order_no="111" segment_no="16" tag_type="text">Section 6.4). Based on their review of the available</text>
<text top="689" left="318" width="238" height="9" font="font6" id="p1_t115" reading_order_no="112" segment_no="16" tag_type="text">evidence, the DSG considered several interpretations</text>
<text top="699" left="318" width="221" height="9" font="font6" id="p1_t116" reading_order_no="113" segment_no="16" tag_type="text">for the use of alemtuzumab in patients with CLL .</text>
<text top="711" left="336" width="221" height="9" font="font6" id="p1_t117" reading_order_no="114" segment_no="19" tag_type="text">The DSG regards alemtuzumab to be an active</text>
<text top="722" left="318" width="239" height="9" font="font6" id="p1_t118" reading_order_no="115" segment_no="19" tag_type="text">agent for the treatment of patients with relapsed or</text>
</page>
</pdf2xml>
